NEW YORK – Scope Biosciences has secured €1 million ($1.2 million) in follow-on investment to scale its molecular diagnostics platform. The diagnostics developer said on Monday that the investment ...

The acquisition is intended to expand the French firm's presence in sequencing-based infectious disease testing.

The company uses artificial intelligence to detect metabolic patterns from urine samples that indicate prostate cancer.

The clinical lab giant is working with MD Anderson on an LDT for assessing cancer risk to drive uptake of recommended screenings and identify high-risk individuals for evaluation.

The Birmingham, UK, firm hopes to develop a broader test menu with industry partners, using AI and machine-learning approaches.

The University of Chicago spinout said that it will use the money to support the commercialization of its saliva-based sequencing test for oral cancers.

NEW YORK — Gut microbiome health startup 32 Biosciences said on Tuesday that it has raised $6 million in private funding, which it said will support the development of its first products.

NEW YORK – Quest Diagnostics said Tuesday that it is collaborating with the University of Texas MD Anderson Cancer Center to develop and validate a laboratory-developed test to identify individuals ...

NEW YORK – Digital pathology firm Paige and the nonprofit Breast International Group said Tuesday that they have formed a partnership to study the use of Paige's artificial intelligence-based test for ...